Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)
Sponsored by AbbVie
About this trial
Last updated 6 years ago
Study ID
P14-152
Status
Completed
Type
Observational
Placebo
No
Accepting
All
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 8 years ago
What is this trial about?
This investigation was conducted to obtain the following information regarding the use of
Adalimumab (Humira®) 40mg Syringe 0.8mL for Subcutaneous Injection in patients with
Intestinal Behcet's Disease.
1. Incidence and conditions of occurrence of adverse reactions in clinical practice
2. Factors likely to affect the safety and effectiveness
What are the participation requirements?
Inclusion Criteria
- All patients who received Adalimumab for the treatment of Intestinal Behcet's disease (not sufficiently responsive to existing therapies, e.g. steroids, immunomodulator)
Exclusion Criteria
Contraindications according to the Package Insert include patients who had any of the following: - serious infections - tuberculosis - a history of hypersensitivity to any ingredient of Humira® - demyelinating disease or a history of demyelinating disease - congestive cardiac failure
View clinical trial results on registries
For more information, view the full study details:
NCT01960790